

Alteration in the expression of microRNA-21 regulated target genes: Role in breast cancer

PRIYANKA THAKUR¹; REENA V. SAINI^{2,3,*}; ANIL K. CHHILLAR⁴; NEERAJ K. SAINI⁵; VIJAY KUMAR THAKUR⁶;
SAMARJEET SINGH SIWAL⁷; ADESH K. SAINI^{2,3,*}

¹ Faculty of Sciences, Shoolini University, Solan, 173229, India

² Department of Biotechnology, MMEC, Maharishi Markandeshwar (Deemed to be University), Ambala, 133207, India

³ Maharishi Markandeshwar University, Solan, 173229, India

⁴ Centre of Biotechnology, Maharshi Dayanand University, Rohtak, 124001, India

⁵ School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India

⁶ Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), Edinburgh, EH9 3JG, UK

⁷ Department of Chemistry, MMEC, Maharishi Markandeshwar (Deemed to be University), Ambala, 133207, India

Key words: Non-coding RNA, microRNAs, Breast cancer, Tumor suppression, Biomarker

Abstract: Breast cancer, also recognized as the principal cause of cancer-related deaths among women, is the second most familiar and prevalent form of cancer. New diagnostic and prognostic biomarkers that are highly specific are urgently needed for its early prognosis. MicroRNAs (miRNAs), a class of non-coding RNAs, are known to control the biological processes involving transcription, post-transcriptional and covalent modifications, splicing, translation, cell differentiation, proliferation, apoptosis, cancer progression, and invasion. Any dysregulation in miRNA expression, demonstrating their oncogenic and tumor-suppressive functions, contributes to cancer progression. MicroRNA-21 (miR-21), an 'onco-miR' in breast cancer, is involved in tumor progression and metastasis by suppressing the activity of the target gene via its interaction with the 3'UTR of the target gene. The upregulation of miR-21 is observed in many instances of breast cancer. Our review aims to summarize the current understanding of miR-21 in the regulation of important cellular functions via regulation of its target genes. We discuss its biosynthesis, oncogenic function in breast cancer, and different methods used for its detection. This will increase the current understanding of the role of miR-21 in breast cancer tumorigenesis, which will offer a perception of using miR-21 as an early detection molecular prognostic and diagnostic biomarker and as a therapeutic target in breast cancer care.

Abbreviations

Her2: Human epidermal growth factor receptor 2
ncRNAs: Noncoding RNAs
miRNAs: MicroRNAs
piRNA: PIWI-interacting RNAs
circRNAs: Circular RNAs
lncRNAs: Long noncoding RNAs
miR-21: MicroRNA-21
pre-miR-21: Precursor miR-21
pri-miRNA: Primary-miRNA
SNP: Single nucleotide polymorphism

m6A: N(6)-methyladenosine
HNRNPA2/B1: Heterogeneous nuclear ribonucleoprotein A2/B1
RISC: RNA-induced silencing complex
AGO2: Argonaute 2
miRISC: miRNA-induced silencing complex
Dcp 1: Decapping protein 1
Dcp 2: Decapping protein 2
XRN1: Exoribonuclease 1
qRT-PCR: Quantitative reverse transcription polymerase chain reaction
NGS: Next-generation sequencing
PDCD4: Programmed cell death 4
TPM1: Tropomyosin-1
PTEN: Phosphatase and tensin homolog
MASPIN: Mammary serine protease inhibitor

*Address correspondence to: Adesh K. Saini, sainiade@mmumullana.org;
Reena V. Saini, reenavohra10@mmumullana.org
Received: 09 April 2021; Accepted: 07 June 2021



Bcl-2:	B-cell lymphoma 2
LZTFL1:	Leucine zipper transcription factor-like 1
PRMT5:	Protein arginine methyltransferase 5
OSCC:	Oral squamous cell carcinoma
2-DIGE:	Two-dimensional differentiation in-gel electrophoresis
anti-miR-21:	Antisense miR-21
PIP:	Phosphatidylinositol phosphate
FAP:	Fibroblast activation protein
EMT:	Epithelial-mesenchymal transition
MAPK:	Mitogen-activated protein kinase

Introduction

The second most complex and heterogeneous cancer which brings mortality in 45–55 years older women across the world is breast cancer (Hemmatzadeh *et al.*, 2016; Wang *et al.*, 2017; Becker, 2015; Quan *et al.*, 2020; Ataollahi *et al.*, 2015). Aging is one of the most significant recognized risk factors associated with breast cancer. However, other risk factors such as deficiency of iodine, high estrogen level, obesity, intake of alcohol, menopause, family history, physically inactive and chest radiation exposure are also involved in breast cancer (Yager and Davidson, 2006; Steiner *et al.*, 2008; Stoddard *et al.*, 2008; Ataollahi *et al.*, 2015). Breast cancer occurs in tissues that include mammary glands and ducts, resulting in lumps, swelling, redness, irritation in breast skin and nipples discharge (Ataollahi *et al.*, 2015). The breast cancer cells are categorized into six major subtypes based on their phenotype and gene expression profile, including i) luminal A, ii) luminal B, iii) tumor enriched with human epidermal growth factor receptor 2 (also known as Her2), iv) basal-like (triple-negative), v) normal-like, and vi) claudin-low subtype (Singh and Mo, 2013; Sørlie *et al.*, 2003; Eroles *et al.*, 2012).

It is believed that the mortality rate due to breast cancer can be reduced through the early diagnosis and detection of these six subtypes (Imani *et al.*, 2017). The mammographic screening tool is the most operative tool used for the early diagnosis of tissue-based tumors in the breast (Taplin *et al.*, 2008; Imani *et al.*, 2017). But this tool has certain limitations such as high false-positive results, low reactivity, and low preciseness and, not adequate to diagnose the subtypes, so there is a need for new diagnostic and prognostic biomarkers that are highly specific (Adhami *et al.*, 2018; Imani *et al.*, 2017). Various non-coding RNAs (ncRNAs) that involve microRNAs (miRNAs), PIWI-interacting RNAs (piRNA), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs) are found to regulate biological processes like transcription, post-transcriptional modifications, covalent modifications, splicing, and translation in the metastasis phase of breast cancer cells (Klinge, 2018). Of all the ncRNAs studied in breast cancer, miRNAs are the most thoroughly studied and have diagnostic potential (Lo *et al.*, 2016).

miRNA in breast cancer

miRNAs perform a crucial function in cancer research as predictive, diagnostic and, prognostic biomarkers because of their regulatory roles in vital processes of life like cell

differentiation, proliferation, apoptosis, cancer progression and invasion (Kim, 2005; O'Day and Lal, 2010; Yu and Cheah, 2017). miRNAs are 15–27 nucleotides, short endogenous ncRNA molecules that are well known for post-transcriptionally regulating gene expression in eukaryotes by base pairing with protein-coding mRNA genes 3'-UTR (Feng and Tsao, 2016; Han *et al.*, 2016; Wilczynska and Bushell, 2015; Adhami *et al.*, 2018). Around half of the human miRNAs are placed on human cancer-related chromosomal regions (fragile sites), enabling them to alter the tumor suppressor or oncogenic pathways (Calin *et al.*, 2004; Hemmatzadeh *et al.*, 2016; Tang *et al.*, 2012; Casalini and Iorio, 2009; Croce, 2009). Various studies have shown the miRNAs involvement as oncogenic/tumor suppressor in the pathogenesis of breast cancer as defined in Tab. 1 (Zhu *et al.*, 2008; Si *et al.*, 2007; Yan *et al.*, 2008; Kong *et al.*, 2012; Hassan *et al.*, 2012; Fabian and Sonenberg, 2012).

In breast cancer, microRNA-21 (miR-21) is the key miRNA used in the invasion process and facilitates tumor progression and metastasis (Han *et al.*, 2012a; Han *et al.*, 2012b). miR-21, also identified as MIR21, hsa-mir-21, miRNA21, MIRN21, is located on chromosome 17q21.3 encoding 72-nt long precursor miR-21 (pre-miR-21) (Abdel-hamid *et al.*, 2015; Hemmatzadeh *et al.*, 2016). By targeting multiple tumor/metastasis suppressor genes, miR-21 functions as an oncogene (Abdel-hamid *et al.*, 2015; Hemmatzadeh *et al.*, 2016; Selcuklu *et al.*, 2009). The upregulated expression of miRNA-21 has been correlated with lymph node metastasis, advanced tumor levels and poor prognosis; therefore, it can act as a prognostic marker in breast cancer (Yan *et al.*, 2008; Hemmatzadeh *et al.*, 2016; Lee *et al.*, 2011; Li *et al.*, 2016; Shen *et al.*, 2015).

Biosynthesis of miRNA

In the nucleus, the RNA polymerase II transcribes non-coding miRNA gene into 100–120 nt long hair pin structured primary-miRNA (pri-miRNA) (Petri and Klinge, 2020; Lee *et al.*, 2004; Yu and Cheah, 2017) (as shown in Fig. 1). The enzymes DROSHA (a class 2 ribonuclease III) and DGCR8 (dsRNA-binding protein) cleave the hair pin structure of pri-miRNA to produce 70 nt pre-miRNA (Filippov *et al.*, 2000; Gregory *et al.*, 2004; Denli *et al.*, 2004). DROSHA (encoded by miRNA machinery gene) is responsible for processing miRNA in the initial phase (Khan *et al.*, 2014). The pri-miRNA is further modified by the N(6)-methyladenosine (m6A) post-transcriptionally, stimulating the beginning of the miRNA biosynthesis process (Alarcón *et al.*, 2015a). The heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2/B1) attaches to m6A in pri-miRNA, assisting DROSHA's transformation of pri-miRNA into pre-miRNA (Alarcón *et al.*, 2015b). After trimming of pri-miRNA, Exportin 5 (encoded by XPO5) or Exportin 1 (encoded by XPO1) exports pre-miRNA to the cytoplasm for further processing by the Dicer enzyme (Sheng *et al.*, 2018). DROSHA plays a very significant role. The single nucleotide polymorphism (SNP) located in the 3'UTR of DROSHA rs10719 has been linked to breast cancer risk because it abrogates the hsa-miR-1298 binding site in DROSHA, thus affecting its expression (Khan *et al.*, 2014).

TABLE 1

Oncogenic and tumor suppressor miRNAs target genes in breast cancer

miRNA	Target Genes	Role	References
Oncogenic miRNAs			
miR-21	<i>Bcl-2, PDCD4, TPM1, PTEN, MASPIN, LZTFL1</i>	Apoptosis; cell proliferation; β -catenin nuclear signaling; EMT process regulator	Si <i>et al.</i> , 2007; Zhu <i>et al.</i> , 2007; Frankel <i>et al.</i> , 2008; Qi <i>et al.</i> , 2009; Zhu <i>et al.</i> , 2008; Gong <i>et al.</i> , 2014; Wang <i>et al.</i> , 2019
miR-155	<i>RHOA, SOX1, SOCS1, MMP16, PTEN, DUSP14, PIK3R1, FOXO3a, ZEB2, TSPAN5</i>	TGF- β /Smad pathway; cell proliferation and migration; PIK3R1-FOXO3a-cMYC pathway; cell invasiveness; miR-155/TSPAN5 signaling axis	Kong <i>et al.</i> , 2008; Zhang <i>et al.</i> , 2018; Kia <i>et al.</i> , 2019; Kim <i>et al.</i> , 2018; Brown <i>et al.</i> , 2018; Yang <i>et al.</i> , 2020
miR-373/520c	<i>CD44, IL-8, ESR1, TXNIP, RABEP1, RELA, TGFB2</i>	Oncogene-induced p53 pathway; metastasis; EMT process; pro-metastatic	Tang <i>et al.</i> , 2017; Eichelser <i>et al.</i> , 2014; Huang <i>et al.</i> , 2008; Yan <i>et al.</i> , 2011; Keklikoglou <i>et al.</i> , 2012
miR-9	<i>LIFR, E-cadherin, PTEN, DUSP14, FOXO1, AR, ESR1, STARD13, SOCS3, PIAS3, ONECUT2</i>	Cellular differentiation; Metastasis; cell proliferation, migration, and invasion; oestrogen regulated pathway; JAK/STAT signaling pathway; androgen receptor pathway; blockhe EV miRNA-ONECUT2 axis	Ma <i>et al.</i> , 2010; Chen <i>et al.</i> , 2012; Kia <i>et al.</i> , 2019; Liu <i>et al.</i> , 2017; Moazzeni <i>et al.</i> , 2017; Barbano <i>et al.</i> , 2017; Li <i>et al.</i> , 2020; Jiang <i>et al.</i> , 2020; Bandini <i>et al.</i> , 2020; Shen <i>et al.</i> , 2019
miR-10b	<i>RHOC, HOXD10, MAPRE1, PIEZO1, SRSF1, TP53, CDKN2A, TRA2B, FUT8, NR4A3, TBX5, PTEN, NF1, KLF4</i>	Metastasis; cell proliferation and invasion; AKT signaling pathway; transcriptional misregulation; pro-metastatic; EMT process; adhesion and migration	Ma <i>et al.</i> , 2007; Ma <i>et al.</i> , 2010; Meerson <i>et al.</i> , 2019; Guo <i>et al.</i> , 2018; M'hamed <i>et al.</i> , 2017; Kim <i>et al.</i> , 2018; Kim <i>et al.</i> , 2016; Negrini and Calin, 2008
miR-196a	<i>ANXA1, SPRED1, annexin-A1</i>	Cell proliferation; estrogen signaling	Luthra <i>et al.</i> , 2008; Jiang <i>et al.</i> , 2018; Rahim <i>et al.</i> , 2019
miR-221/222	<i>Era, p27^{kip1}, p57, PTPμ, PTEN, Bim, TIMP3, SOCS3, Notch3, A20 (TNFAIP3), c-Rel, CTGF, GAS5</i>	Signaling pathways (Wnt, TGF- β , p53, MAPK, Notch, Erb B and Jak-STAT); focal adhesion; Wnt/ β -catenin signaling; A20/c-Rel/CTGF signaling; Akt/NF- κ B/COX-2 pathway; promotes EMT process; anti-apoptosis; cell proliferation	Rao <i>et al.</i> , 2011; Garofalo <i>et al.</i> , 2012; Liang <i>et al.</i> , 2018; Li <i>et al.</i> , 2017; Liu <i>et al.</i> , 2018; Santolla <i>et al.</i> , 2018; Zong <i>et al.</i> , 2019; Chen <i>et al.</i> , 2020; Tang <i>et al.</i> , 2019
Cluster 17/20 (miR-17-3p, miR-17-5p, miR-18, miR-19a, miR-19b, miR-20, and miR-92)	<i>AIB1, cyclin D1, STAT3, FOSL (Fra-1), IMPDH1, NPEPL1, PTEN, BRCA2, VEZF1</i>	Cell proliferation by Wnt, β -Catenin; LEF1 pathway; apoptosis; pro-metastatic; pro-angiogenesis	Hossain <i>et al.</i> , 2006; He <i>et al.</i> , 2005; Mu <i>et al.</i> , 2019; Liao <i>et al.</i> , 2017; Yang <i>et al.</i> , 2013
Tumor Suppressor miRNAs			
miR-206	<i>ESR1, NAMPT, MKL1, IL11, TWF1, SRF, WDR1, MRTF-A, neurokinin-1, WBP2</i>	ER signaling; inhibition of stemness and metastasis; cell migration and progression; modulation of tamoxifen sensitivity	Iorio <i>et al.</i> , 2005; Adams <i>et al.</i> , 2007; Samaeekia <i>et al.</i> , 2017; Xiang <i>et al.</i> , 2017; Zhou <i>et al.</i> , 2019; Hesari <i>et al.</i> , 2018; Ren <i>et al.</i> , 2017
miR-125a, b	<i>HER2, HER3, KIAA1522, BAP1</i>	Anchorage-dependent growth; differentiation; cell proliferation, migration and invasion	Mattie <i>et al.</i> , 2006; Scott <i>et al.</i> , 2007; Iorio <i>et al.</i> , 2005; Li <i>et al.</i> , 2018; Yan <i>et al.</i> , 2018
miR-34a	<i>Bcl-2, SIRT1, CCND1, CDK6, E2F3, MYC, ErbB2, Notch1, C22ORF28</i>	DNA damage; cell proliferation; drug resistance; FOXM1/eEF2K signaling axis	Li <i>et al.</i> , 2013; Christoffersen <i>et al.</i> , 2010; Welch <i>et al.</i> , 2007; Sun <i>et al.</i> , 2008; Wang <i>et al.</i> , 2017; Li <i>et al.</i> , 2017; Bayraktar <i>et al.</i> , 2018; Lin <i>et al.</i> , 2017; Rui <i>et al.</i> , 2018
miR-200	<i>BMI-1, ZEB1, ZEB2, QKI, MYB</i>	TGF- β signaling; EMT process; tamoxifen resistance	Uhlmann <i>et al.</i> , 2010; Cochrane <i>et al.</i> , 2010; Gregory <i>et al.</i> , 2008; Dykxhoorn <i>et al.</i> , 2009; Shimono <i>et al.</i> , 2009; Kim <i>et al.</i> , 2019; Gao <i>et al.</i> , 2019

(Continued)

Table 1 (continued).

miRNA	Target Genes	Role	References
miR-17-5p	<i>AIB1, CCND1, E2F1, STAT3</i>	Proliferation; apoptosis	Hossain <i>et al.</i> , 2006; Yu <i>et al.</i> , 2008; Liao <i>et al.</i> , 2017
miR-31	<i>FZD3, ITGA5, M-RIP, MMP16, RDX, RHOA, Dkk1</i>	Metastasis; Wnt/ β -catenin	Valastyan <i>et al.</i> , 2009; Lv <i>et al.</i> , 2017
let-7	<i>RAS, HMGA-2, H-RAS, LIN28, PEBP1, MCY, CCND1, CYP19A1, MAGE-A1, ADRB2, HIFIAN, CLDN12, MZF1</i>	Proliferation, differentiation; EMT pathway; EMC receptor interaction; pro-metastatic; angiogenesis; migration and invasion	Yu <i>et al.</i> , 2007; Mayr <i>et al.</i> , 2007; Wu <i>et al.</i> , 2006; Johnson <i>et al.</i> , 2005; Song <i>et al.</i> , 2020; Qattan <i>et al.</i> , 2017; Shibahara <i>et al.</i> , 2012; Mi <i>et al.</i> , 2019; Du <i>et al.</i> , 2019; Tvingsholm <i>et al.</i> , 2018
miR-205	<i>HER3, RunX2, HMGB1-RAGE, SIPR1</i>	P13K/Akt pathway; regulates the activity of CD44 ⁺ /CD24 ⁻ breast cancer stem cells; EMT process and cell invasion	Iorio <i>et al.</i> , 2009; Wang <i>et al.</i> , 2019; Fang <i>et al.</i> , 2020
miR-7	<i>PaK-1, FAK, PAK1, EGFR, KLF4, HoxB3, SET8, BRCA1, LASP1, RELA, MRP1, BCL2</i>	Anchorage independence; invasiveness; motility; inhibition of ESAM expression; reverses chemotherapy resistance	Reddy <i>et al.</i> , 2008; Zhao <i>et al.</i> , 2015; Moazzeni <i>et al.</i> , 2017; Li <i>et al.</i> , 2020; Hong <i>et al.</i> , 2019
miR-30a	<i>SNAIL1, Vimentin, Notch1, Snail, ROR1, Slug, TWIF1, vimentin, UBE3C</i>	Motility and invasiveness; EMT and metastasis; inhibition of cell viability and migration; apoptosis	Cheng <i>et al.</i> , 2012; Wang <i>et al.</i> , 2018; Kawaguchi <i>et al.</i> , 2017; Zhang <i>et al.</i> , 2017; Xiao <i>et al.</i> , 2019

Dicer is a RNase III class of enzyme that cleaves the hair pin region of pre-miRNA to produce 20–30 nts of duplex miRNA composed of two single guide (5' to 3') and passenger (3' to 5') strands (Kobayashi and Tomari, 2016; Höck and Meister, 2008; Petri and Klinge, 2020). This guide strand joins the PAZ domain of RNA-induced silencing complex (RISC) to mediate post-transcriptional gene silencing of the target mRNA through Argonaute 2 (AGO2, RNase, catalytic part of RISC having “slicer” activity) which cleaves the target mRNA and the PIWI domain of RISC is responsible for the degradation of passenger strand (Höck and Meister, 2008; MacFarlane and Murphy, 2010; Yu and Cheah, 2017).

miRNA-induced silencing complex (miRISC, composed of AGO2 and guide strand) mediate the degradation of target mRNA. miRISC follows Ago-catalyzed, decapping, deadenylation, and exonucleolytic mechanisms (Eulalio *et al.*, 2008; Behm-Ansmant *et al.*, 2006; Wahid *et al.*, 2010). Once miRNA and target mRNA complement each other, AGO2's endonuclease activity is activated, cleaving the target mRNA (MacFarlane and Murphy, 2010). The miRISC inhibits the translation by obstructing the eIF4F complex, and mRNA circularization process of the target mRNA (Wahid *et al.*, 2010). The GW182 family proteins bind to AGO2 are recruited by miRISC and act as a scaffold for the complex poly(A)-deadenylase PAN2-PAN-3 and CCR4-NOT proteins (MacFarlane and Murphy, 2010; O'Brien *et al.*, 2018). The poly(A)-deadenylation process is initiated by the PAN2-PAN3 complex and completed by the CCR4-NOT protein complex. This process is further enhanced through the interaction of poly(A)-binding protein (PABPC) and GW182 tryptophan (W)-repeats (MacFarlane and Murphy, 2010; O'Brien *et al.*, 2018). The exosome (with 3'-5' exonuclease activity) mediates the degradation process and the enzymes, decapping protein 1 (Dcp 1) and

decapping protein 2 (Dcp 2) facilitate the process by inducing exoribonuclease 1 (XRN1), which target 5'-3' mRNA degradation (MacFarlane and Murphy, 2010; O'Brien *et al.*, 2018).

Identifying miRNA in breast cancer cells

miRNAs have crucial role in gene regulation, so it is becoming imperative to develop and improve methods that can detect miRNAs because their detection in breast cancer is difficult due to their small size, low abundance, high level of sequence similarities (Chandrasekaran *et al.*, 2019; Ye *et al.*, 2019). The most well-known traditional methods for the detection of miRNA are microarray, *in situ* hybridization, bead-based flow cytometry, next-generation sequencing (NGS), northern blotting, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) (Ye *et al.*, 2019; van Schooneveld *et al.*, 2015). Out of these methods, northern blotting and *in situ* hybridization are low throughput methods, whereas microarray, bead-based flow cytometry, qRT-PCR and NGS are high throughput methods (van Schooneveld *et al.*, 2015).

Northern blotting is the most standardized and highly specific method that can detect mature miRNA and their precursors (Ye *et al.*, 2019; Várallyay *et al.*, 2008). Besides these, the northern blotting method has a poor sensitivity and cannot detect the RNAs present in low amounts in few cells (Ye *et al.*, 2019). qRT-PCR method is a highly sensitive and specific method used for evaluating miRNA and for the authentication of data prevailed from other detection platforms (Balcells *et al.*, 2011; Yu and Cheah, 2017). The bead-based flow cytometry method is moderate in sensitivity and strong in specificity, whereas the *in situ* hybridization method is low in sensitivity and specificity (van Schooneveld *et al.*, 2015). Microarray is a rapid method that can examine plenty of miRNAs from vast numbers of samples, with low

sensitivity and specificity (Li and Ruan, 2009; Cissell and Deo, 2009). All these methods recognize only known miRNA structures, but NGS is the latest high sensitivity and specificity approach that enables new miRNAs to be recognized (van Schooneveld *et al.*, 2015; Creighton *et al.*, 2009). In the case of breast cancer, the upregulated levels of miR-21 can also be detected from tissues, blood, and serum (Yu and Cheah, 2017; Savad *et al.*, 2012).

Oncogenic role of miR-21 in breast cancer cell proliferation and metastasis

The “oncomiR” *miR-21* is believed to be involved in tumor proliferation and metastasis in breast tissues by controlling the expression of tumor suppressor genes such as *programmed cell death 4 (PDCD4)*, *tropomyosin-1 (TPM1)*, *phosphatase and tensin homolog (PTEN)*, *mammary serine protease inhibitor (MASPIN)*; an apoptosis suppressor gene, *B-cell lymphoma 2 (Bcl-2)*, and leucine zipper transcription factor-like 1 gene [(*LZTFL1*), a tumor suppressor] (Si *et al.*, 2007; Zhu *et al.*, 2007; Frankel *et al.*, 2008; Qi *et al.*, 2009; Zhu *et al.*, 2008; Wei *et al.*, 2010; Wang *et al.*, 2019) (illustrated in Fig. 2). These genes play a critical role in breast cancer and are targeted by miR-21.

Programmed Cell Death 4 (PDCD4)

In both immune/non-immune cells, the programmed cell death 4 gene is a tumour suppressor (Jiang *et al.*, 2017). The PDCD4 protein contains three domains (two MA-3 domains and the N-terminal domain) that play a role in transcription and translation inhibition (Jiang *et al.*, 2017). Owing to the binding of its MA-3 domains to eIF4A, PDCD4 prevents the translation of mRNAs having structured 5'UTRs, hindering eIF4A binding to eIF4G, even blocking eIF4A's helicase activity, thus repressing the translation initiation mechanism of many genes, such as *p53*, *Atg5*, *pro-caspase 3*, and *LXR-α* (Kroczyńska *et al.*, 2012; Yang *et al.*, 2004). By interacting with its N-terminal domain with A-myb & c-myb (RNA secondary structures), PDCD4 represses the elongation mechanism of translation (Singh *et al.*, 2011). PDCD4 prevents tumor cell proliferation and invasion via inducing their apoptosis, leading to its upregulation in various tumors like breast, ovarian, gastric, esophageal, lung, hepatocellular, colon and glioma tumors (Powers *et al.*, 2011; Wei *et al.*, 2012; Jiang *et al.*, 2017). The protein arginine methyltransferase 5 (PRMT5) deregulates the activity of the PDCD4 gene, resulting in breast cancer cell proliferation and invasiveness (Powers *et al.*, 2011). miR-21 has been shown to target PDCD4 in tumour cells, thereby downregulating its expression (Sheedy *et al.*, 2010).

PDCD4 is a target of miR-21 for breast cancer (Frankel *et al.*, 2008). The miR-21 binding sites in the PDCD4 3'UTR are shown in Fig. 3A, which shows how miR-21 interacts with the PDCD4 3'UTR. To assess the fact that miR-21 specifically targets PDCD4, the firefly luciferase reporter assay was carried out. Frankel and his colleagues first cloned PDCD4's 400–500 bp of 3'UTR into the pGL3 vector and then developed single (pGL3-PDCD4MUT1) and double (pGL3-PDCD4MUT2) mutations in the pGL3-PDCD4 seed region. pGL3-PDCD4, pGL3-PDCD4MUT1 & pGL3-PDCD4MUT2 were transfected into HEK293 cells and luciferase activity was tested after 24 h.

Results showed that miR-21 had no effect on pGL3-PDCD4MUT2 regulation but had little effect on pGL3-PDCD4MUT1 regulation (as shown in Fig. 3B), leading to the inference that there is a clear association between miR-21 and PDCD4 seed region 3'UTR. To verify the effects of miR-21 inhibition, they knocked down PDCD4 in MCF-7 cells via siRNA and found that PDCD4 siRNA mediated the antiproliferative effect on MCF-7 cells (see Figs. 3C, D). Thus, revealing the significance of PDCD4 by miR-21 as a putative target for breast cancer (Frankel *et al.*, 2008).

Another research by Zhu *et al.* (2008) showed that miR-21 interacted with PDCD4's 3'UTR, resulting in its reduced expression in MDA-MB-231 cells. Anti-miR-21 also led to increased PDCD4 expression, indicating the role of miR-21 in breast cancer cell invasion by directly interacting with the PDCD4 target gene (Zhu *et al.*, 2008).

Tropomyosin-1 (TPM1)

Tropomyosin-1, also known as *TM1* and the actin-binding cytoskeletal protein, is a TPM family isoform that functions as a tumour suppressor gene by preventing cancer cell invasion by persuading apoptosis (Wang *et al.*, 2015; Pan *et al.*, 2017; Qi *et al.*, 2009; Wang *et al.*, 2019). Downregulation of TPM1 has been observed in breast cancer, glioma cancer, renal cell carcinoma, human oral squamous cell carcinoma (OSCC), and cholangiocarcinoma (Wang *et al.*, 2015; Dube *et al.*, 2015; Pan *et al.*, 2017; Bharadwaj and Prasad, 2002; Yang *et al.*, 2013; Ku *et al.*, 2010). The expression of TPM1 in the OSCC is regulated by miR-21 (Pan *et al.*, 2017). In addition, Zhu *et al.* (2007) in their report, showed that TPM1 is targeted by miR-21 in breast cancer to inhibit the TPM1 mediated apoptosis of cancer cells. They conducted two-dimensional differentiation in-gel electrophoresis, where they found the upregulated TPM1 expression in tumors procured from MCF-7 cells by antisense miR-21 oligonucleotides (anti-miR-21). miR-21 controls TPM1 expression by base-pairing with the V1 variant 3'UTR of TPM1, including miR-21's putative binding sites. For further evidence, the V1-3'UTR was cloned into a luciferase reporter. Luciferase assay results suggested that anti-miR-21 increased Luc-TPM1-V1-UTR activity, while miR-21 decreased its activity. Moreover, the effect of miR-21 inhibition on TPM1 was also tested at the level of translation. MTT assay revealed that TPM1-V1 repressed the growth of MCF-7 cells *in vitro*, and soft agar assay results also showed that TPM1-V1 reduced colony formation leading to anchorage-independent growth repression. Altogether, we can conclude that miR-21 uses TPM1 to control its expression in MCF-7 cells as a novel target.

Phosphatase and tensin homolog (PTEN)

PTEN on chromosome 10 is recognized as a tumor suppressor gene coding 403 amino acids protein, which functions as a metabolic regulator of a number of cellular processes like glycogen synthesis, lipid and mitochondrial metabolism, glycolysis, and gluconeogenesis (Chen *et al.*, 2018). It has dephosphorylation activities for both proteins and lipids due to which it is known as dual phosphatase enzyme (Chu and Tarnawski, 2004). PTEN has five domains: 1) N-terminal domain, responsible for the binding of phosphatidylinositol phosphate (PIP) substrates; 2) Phosphatase domain, carries




FIGURE 1. Biosynthesis of miRNA. RNA polymerase II is responsible for the transcription of 100–120 nts pri-miRNA in the nucleus. The pri-miRNA is trimmed into 70 nts pre-miRNA by DROSHA and DGCR8, which is then exported by exportin 5/1 into the cytoplasm, where it is further processed by Dicer enzyme forming 20–30 nts duplex miRNA with the guide (5' to 3') and passenger (3' to 5') strands. The guide strand interacts with the PAZ domain of the RISC, causing Argonaute 2 (AGO2) to cause post-transcriptional gene silencing and cleavage of the target mRNA, while the RISC's PIWI domain degrades the passenger strand.

acetylation sites and CX5R signature motif for the enzymatic actions; 3) C2 domain, a regulatory domain which contains a phospholipid-binding site and known for PTEN cell localization; 4) C-tail, which preserves phospho-sites and is responsible for the stability of protein; 5) PDZ domain, which is not well known (as shown in Fig. 4) (Chu and Tarnawski, 2004; Jerde, 2015; Chen et al., 2018). PTEN has regulatory functions in several processes, including cell

migration, cell cycle arrest, MAP kinase signaling and angiogenesis (Chu and Tarnawski, 2004). Any mutations in PTEN gene lead to the progression of sporadic breast cancer, renal cell carcinoma, ovarian cancer, lung cancer, thyroid cancer, lymphoma cancer, hepatocellular carcinoma, lymphoma, head & neck cancer, prostate cancer, and glioblastoma (Chu and Tarnawski, 2004; Meng et al., 2007; Halachmi et al., 1998; Shao et al., 1998; Forgacs et al., 1998;




FIGURE 4. Protein domains of PTEN (Jerde, 2015).

Saito *et al.*, 2000). In human hepatocellular cancer, miR-21 is known to regulate the *PTEN* expression and pathways which are mediated by *PTEN* (Meng *et al.*, 2007).

A research conducted by Gong *et al.* (2014) showed that miR-21 decreases *PTEN* expression in tumors of breast phyllodes. Like *PDCD4* and *TPM1*, *PTEN* also has miR-21 binding sequences at 3'UTR (Zhu *et al.*, 2007; Frankel *et al.*, 2008; Gong *et al.*, 2014). *PTEN* protein levels were increased via miR-21 antisense oligonucleotides while, decreased via miR-21 mimics in stromal fibroblasts, demonstrating the role of miR-21 in targeting *PTEN* to increase the proliferation of phyllodes tumors cells (Gong *et al.*, 2014). *PTEN* is known for the regulation of fibroblast activation protein (FAP) function (FAP is familiar as a serine protease and myofibroblast marker to increase the proliferation of phyllodes tumors) (Liu *et al.*, 2012; Gong *et al.*, 2014). The *PTEN* knockdown raised the protein expression levels of FAP during the myofibroblast differentiation process, suggesting the role of *PTEN* in proliferation. Moreover, reintroduction of *PTEN* resulted in a decrease in both *PTEN* mRNA and protein levels in benign tumors, thus inhibiting the proliferation of tumor cells by miR-21. Together, these findings concluded that miR-21 downregulates the *PTEN* expression to induce cell proliferation by increasing FAP expression in breast phyllodes tumor (Gong *et al.*, 2014).

Mammary Serine Protease Inhibitor (MASPIN)

Mammary serine protease inhibitor is related to the serpin family (serine protease inhibitor family) (Zhang, 2002). Due

to its ability to prevent tumor invasion by inducing apoptosis in tumor cells found on the 18q21.3-q23 chromosome, it is also recognized as a tumor suppressor gene (Berardi *et al.*, 2013; Zhang, 2002). It is also known to prevent the process of angiogenesis (Zhang, 2002). Owing to its nuclear/cytoplasmic location in cancer cells, its expression is downregulated in various cancers like breast, gastric, prostate, melanoma and upregulated in gallbladder, thyroid, colorectal, pancreatic cancers (Berardi *et al.*, 2013).

Maspin decreased MDA-MB-231 tumour cell invasion in the case of breast cancer (Zhu *et al.*, 2008). With Flag-tagged maspin, they transfected MDA-MB-231 cells and confirmed the invasiveness of tumour cells through western blotting. However, by targeting it, the oncomir miR-21 downregulated maspin expression in MDA-MB-231 cells. Maspin also has 3'UTR binding sites for miR-21, so they cloned 3'UTR of maspin into pGL3 vector (luciferase gene) to check the Luc-Maspin-3'UTR luciferase activity. They found that miR-21 repression of luciferase activity was greater than 40%. Furthermore, anti-miR-21 increased the maspin expression, leading to the conclusion that by targeting its 3'UTR, miR-21 inhibits the maspin expression in MDA-MB-231 cells (Zhu *et al.*, 2008).

B-cell Lymphoma 2 gene (*Bcl-2*)

B-cell lymphoma 2 is a 26 kDa protein present on human chromosome 18q21 with a hydrophobic carboxyl terminus positioned on the outer mitochondrial membrane and an anti-apoptotic gene as well (Lu *et al.*, 1996). It suppresses




FIGURE 5. The levels of miR-21 in breast cancer patient plasma and cell lines. (A) Plasma miR-21 levels in 252 breast cancer patients, 127 healthy controls, and 82 benign breast cancer patients ($p < 0.0001$). (B) Plasma miR-21 levels in luminal A, luminal B, Her-2+ and basal-like types of breast cancer patients ($p < 0.05$). (C) The mRNA levels of miR-21 in HBL-100, Hs578T, MDA-MB-231, SK-BR-3, and MCF-7 cell lines ($*p < 0.05$, $**p < 0.01$, $***p < 0.001$) (Wang *et al.*, 2019).

LZTFL1 3'-UTR 341-347 nt 5'...UAAUAAAUGUAAAUAAGCUAACAA...3'

hsa-miR-21 3'...AGUUGUAGUCAGAC UAUUCGAU...5'

LZTFL1 3'-UTR mutant 5'...UAAUAAAUGUAAA GUAGCGCAACAA...3'

FIGURE 6. The predicted binding site of miR-21 in the 3'-UTR of wild type and mutant LZTFL1 (Wang *et al.*, 2019).

the caspase-mediated cell death and stimulates cell proliferation by restricting the function of pro-apoptotic proteins, Bak and Bax (Lu *et al.*, 1996; Wickramasinghe *et al.*, 2009). Upregulated levels of bcl-2 gene are found in many cancers like lymphoma, breast, colorectal, thyroid, and cervical (Flangea *et al.*, 2008; Manne *et al.*, 2000; Zhou and Wang, 2015). Research on human glioblastoma U87MG cells revealed that miR-21 overexpression resulted in decreased Bax expression and increased bcl-2 gene expression along with reduced caspase-3 activity (Shi *et al.*, 2010). Similarly, miR-21 controls tumorigenesis by upregulating the expression of the bcl-2 gene in breast cancer as miR-21 was highly overexpressed in breast tumors compared to the matched normal breast tissues 157 human miRNAs analysed. (Si *et al.*, 2007). To investigate the function of miR-21, MCF-7 cells were transfected with anti-miR-21 oligonucleotide.

They showed that anti-miR-21 inhibits *in vitro* cell growth and tumor growth in the xenograft mouse model. Furthermore, to assess anti-miR-21 induced apoptosis, transfected cells were given Z-VAD-fmk, a caspase inhibitor, to counteract growth inhibition mediated by anti-miR-21. Apoptosis was caused by reduced Bcl-2 protein expression in anti-miR-21 transfected MCF-7 cells. These findings concluded that miR-21 should be used as a therapeutic target for breast cancer because of its essential function in controlling the Bcl-2 gene (Si *et al.*, 2007). In another study, breast cancer cell lines were developed, which are paclitaxel-resistant, and it was shown that down regulation of miR-21 via its mimic enhance the sensitivity against paclitaxel in the developed cell lines and increase the expression of Bcl-2 (Zhao *et al.*, 2015).

Leucine Zipper Transcription Factor-like 1 (LZTFL1)

The 3p21.3 region of the chromosome contains the leucine zipper transcription factor-like 1 (LZTFL1) gene expressed in epithelial cells of a diversity of normal cells (Wei *et al.*, 2010). LZTFL1, a cytoplasmic protein, regulates β -catenin nuclear signaling, ciliary protein trafficking, and the epithelial-mesenchymal transition (EMT) process (Wei *et al.*, 2016). It represses EMT by inhibiting the mitogen-activated protein kinase (MAPK) signaling pathway, which is especially important in lung cancer (Wei *et al.*, 2010; Wei *et al.*, 2019). It functions as a tumor suppressor by stabilizing E-cadherin-mediated adherens junctions and inhibiting β -catenin relocation into the nucleus, preventing cell invasion and EMT-mediated breast cancer metastasis (Wang *et al.*, 2014; Wang *et al.*, 2019). Wang *et al.* (2019) discovered that LZTFL1 could be used as a new target in breast cancer cells via miR-21, facilitating cell invasion and metastasis. miR-21 was found to be upregulated in the plasma of three patient groups and various cell lines.

The level of plasma miR-21 was significantly higher in the breast cancer patient group than the benign breast cancer patient

group and healthy control group (see Fig. 5A), suggesting that plasma miR-21 level may be used as a potential diagnostic biomarker for breast cancer. The histopathological examination showed an upregulated level of miR-21 in breast cancer types Her-2+ and luminal B (as shown in Fig. 5B), and *in vitro* analysis results showed miR-21 upregulate in all cell lines of breast cancer (MDA-MB-231, Hs578T, MCF-7, and SK-BR3) compared to immortalized mammary epithelial (HBL-100) cell line (see Fig. 5C). As demonstrated by luciferase reporter assay, miR-21 directly targets LZTFL1, where miR-21 overexpression resulted in decreased luciferase activity in HEK293T cells transfected with luciferase gene containing either wild-type or mutant 3'UTR of LZTFL1 (see Fig. 6).

The miR-21/LZTFL1/-catenin axis induces the EMT process. The effect of miR-21 inhibition and LZTFL1 knockdown on various EMT markers such as N-cadherin, vimentin, E-cadherin and claudin-1. miR-21 inhibition decreased N-cadherin and vimentin expression while increasing E-cadherin and claudin-1 expression, whereas LZTFL1 knockdown reversed the expression of these markers (as shown in Fig. 7). Immunofluorescence assay




FIGURE 7. miR-21/LZTFL1 regulates β -catenin nuclear translocation and EMT process. The protein levels of EMT markers in Hs578T cells treated with miR-21 inhibitor, LZTFL1 siRNA alone, or combined for 48 h (Wang *et al.*, 2019).

revealed that translocation of β -catenin in the nucleus was increased by miR-21 which contributed to the transcription of snail and slug transcription factors (EMT markers) (as shown in Fig. 7), while LZTFL1 repressed it. Therefore, miR-21 controls EMT by suppressing the LZTFL1, which increases β -catenin nuclear translocation, resulting in breast cancer proliferation and metastasis. This was also proved in BALB/c nude mice inoculated with Hs578T (human breast cancer) cells. miR-21 overexpression increased tumor size, weight, and volume (see Figs. 8A–8C) as well as lymph node invasion (see Figs. 8D and 8E). Furthermore, overexpression of miR-21 increased metastasis in liver and lung tissues (as shown in Figs. 8F and 8G) (Wang et al., 2019).

Summary

There is an extensive role of ‘oncomiR’ miR-21 in various stages breast cancer viz invasion, development, and metastasis. Different studies have demonstrated miR-21 upregulation in breast cancer cells by targeting multiple genes involved in breast cancer tumorigenesis. As mentioned above, miR-21 overexpression, through the

downregulation of tumour suppressor genes, increases cell proliferation (Frankel et al., 2008; Zhu et al., 2007; Gong et al., 2014). miR-21 specifically interacts with PDCD4, TPM1, PTEN, and maspin 3’UTR, contributing to the suppression of apoptotic activities (Frankel et al., 2008; Zhu et al., 2007; Zhu et al., 2008; Gong et al., 2014). It also promotes breast cancer cell proliferation by increasing the bcl-2 gene expression. These studies indicate that alteration in the expression of miR-21 can be a beneficial intervention in the treatment of breast cancer. Various molecular biology-based techniques have been developed to detect the alteration in the expression of miR-21. Besides this, biosensor-based detection of miR-21 is a new area of research that could be more accessible and can help in point-of-care testing (Wang et al., 2020; Meng et al., 2020; Sun et al., 2018). Another sensitive tool to detect miR-21 in breast cancer is DNA–Peptide dendrimer and mass spectrometric method. It would also be essential to understand the role of miRNA in connection with the changing microbiome, which will help in early diagnosis and be used as a therapeutic biomarker (Allegra et al., 2020; Rastogi et al., 2020; Kashyap et al., 2021).




FIGURE 8. miR-21 promotes breast cancer proliferation and metastasis *in vivo*. (A) Xenografted tumors were obtained from miR-21-treated Hs578T and control Hs578T cells *in situ*. (B and C) Tumor weight and volume were observed and recorded in the groups indicated above. (D and E) The number of lymph nodes invaded was determined. (F and G) Liver and lung tissues were obtained, and the metastatic cells were visualized (Wang et al., 2019).

Acknowledgement: Authors acknowledge the support from Maharishi Markandeshwar (Deemed to be University) Mullana and Shoolini University, Solan.

Author Contribution: The authors confirm contribution to the paper as follows: study conception and design: AKS, RVS; data collection: PT, NKS, AC; draft manuscript preparation: PT, VKT, SSS. All authors compared different studies and approved the final version of the manuscript.

Funding Statement: Authors received no specific funding for this study.

Conflicts of Interest: The authors declare that they have no conflicts of interest to report regarding the present study.

References

- Abdel-hamid NR, Mohammed EA, Abbas AH, Badr FM (2015). MicroRNA-21 expression in primary breast cancer tissue among Egyptian female patients and its correlation with chromosome 17 aneusomy. *Molecular Diagnosis & Therapy* **19**: 365–373.
- Adams BD, Furneaux H, White BA (2007). The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor- α (ER α) and represses ER α messenger RNA and protein expression in breast cancer cell lines. *Molecular Endocrinology* **21**: 1132–1147.
- Adhami M, Haghdoost AA, Sadeghi B, Afshar RM (2018). Candidate miRNAs in human breast cancer biomarkers: A systematic review. *Breast Cancer* **25**: 198–205.
- Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF (2015a). HNRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events. *Cell* **162**: 1299–1308.
- Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF (2015b). N⁶-methyladenosine marks primary microRNAs for processing. *Nature* **519**: 482–485.
- Allegra A, Musolino C, Tonacci A, Pioggia G, Gangemi S (2020). Interactions between the MicroRNAs and microbiota in cancer development: Roles and therapeutic opportunities. *Cancers (Basel)* **4**: 805.
- Ataollahi MR, Sharifi J, Paknahad MR, Paknahad A (2015). Breast cancer and associated factors: A review. *Journal of Medicine and Life* **8**: 6.
- Balcells I, Cirera S, Busk PK (2011). Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. *BMC Biotechnology* **11**: 1.
- Bandini E, Fanini F, Vannini I, Rossi T, Plousiou M et al. (2020). miR-9-5p as a regulator of the androgen receptor pathway in breast cancer cell lines. *Frontiers in Cell and Developmental Biology* **8**: 579160.
- Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C et al. (2017). Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. *Scientific Reports* **7**: 1–2.
- Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN et al. (2018). Dual suppressive effect of miR-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. *Clinical Cancer Research* **24**: 4225–4241.
- Becker S (2015). A historic and scientific review of breast cancer: The next global healthcare challenge. *International Journal of Gynecology & Obstetrics* **131**: S36–S39.
- Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E (2006). mRNA degradation by miRNAs and GW182 requires both CCR4: NOT deadenylase and DCP1: DCP2 decapping complexes. *Genes & Development* **20**: 1885–1898.
- Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M et al. (2013). Role of maspin in cancer. *Clinical and Translational Medicine* **2**: 1–9.
- Bharadwaj S, Prasad GL (2002). Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. *Cancer Letters* **183**: 205–213.
- Brown CY, Dayan S, Wong SW, Kaczmarek A, Hope CM et al. (2018). FOXP3 and miR-155 cooperate to control the invasive potential of human breast cancer cells by down regulating ZEB2 independently of ZEB1. *Oncotarget* **9**: 27708–27727.
- Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the National Academy of Sciences of the United States of America* **101**: 2999–3004.
- Casalini P, Iorio MV (2009). MicroRNAs and future therapeutic applications in cancer. *Journal of Buon* **14**: S17–S22.
- Chandrasekaran AR, MacIsaac M, Dey P, Levchenko O, Zhou L, Andres M, Dey BK, Halvorsen K (2019). Cellular microRNA detection with miRacles: microRNA-activated conditional looping of engineered switches. *Science Advances* **5**: eaau9443.
- Chen CY, Chen J, He L, Stiles BL (2018). PTEN: Tumor suppressor and metabolic regulator. *Frontiers in Endocrinology* **9**: 338.
- Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH et al. (2012). LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. *Nature Medicine* **18**: 1511–1517.
- Chen Z, Pan T, Jiang D, Jin L, Geng Y, Feng X, Shen A, Zhang L (2020). The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/ β -catenin signaling pathway. *Molecular Therapy-Nucleic Acids* **19**: 1434–1448.
- Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY et al. (2012). MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. *Breast Cancer Research and Treatment* **134**: 1081–1093.
- Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M et al. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. *Cell Death & Differentiation* **17**: 236–245.
- Chu EC, Tarnawski AS (2004). PTEN regulatory functions in tumor suppression and cell biology. *Medical Science Monitor* **10**: RA235–RA241.
- Cissell KA, Deo SK (2009). Trends in microRNA detection. *Analytical and Bioanalytical Chemistry* **394**: 1109–1116.
- Cochrane DR, Howe EN, Spoelstra NS, Richer JK (2010). Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. *Journal of Oncology* **2010**: 821717.
- Creighton CJ, Reid JG, Gunaratne PH (2009). Expression profiling of microRNAs by deep sequencing. *Briefings in Bioinformatics* **10**: 490–497.
- Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. *Nature Reviews Genetics* **10**: 704–714.
- Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004). Processing of primary microRNAs by the Microprocessor complex. *Nature* **432**: 231–235.

- Du Y, Lin Y, Yin K, Zhou L, Jiang Y, Yin W, Lu J (2019). Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer. *American Journal of Translational Research* **11**: 1748.
- Dube S, Yalamanchili S, Lachant J, Abbott L, Benz P et al. (2015). Expression of tropomyosin 1 gene isoforms in human breast cancer cell lines. *International Journal of Breast Cancer* **2015**: 859427.
- Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A et al. (2009). miR-200 enhances mouse breast cancer cell colonization to form distant metastases. *PLoS One* **4**: e7181.
- Eichelsler C, Stückerath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H (2014). Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. *Oncotarget* **5**: 9650.
- Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A (2012). Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. *Cancer Treatment Reviews* **38**: 698–707.
- Eulalio A, Huntzinger E, Izaurralde E (2008). GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. *Nature Structural & Molecular Biology* **15**: 346.
- Fabian MR, Sonenberg N (2012). The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC. *Nature Structural & Molecular Biology* **19**: 586.
- Fang T, Jiang YX, Chen L, Huang L, Tian XH, Zhou YD, Nagle DG, Zhang DD (2020). Coix seed oil exerts an anti-triple-negative breast cancer effect by disrupting miR-205/S1PR1 axis. *Frontiers in Pharmacology* **11**: 1518.
- Feng YH, Tsao CJ (2016). Emerging role of microRNA-21 in cancer. *Biomedical Reports* **5**: 395–402.
- Filippov V, Solovyyev V, Filippova M, Gill SS (2000). A novel type of RNase III family proteins in eukaryotes. *Gene* **245**: 213–221.
- Flangea C, Potencz E, Mihăescu R, Giju S, Anghel A (2008). Bcl-2 expression in Hodgkin's lymphoma progression. *Romanian Journal of Morphology Embryology* **49**: 357–363.
- Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S et al. (1998). Mutation analysis of the PTEN/MMAC1 gene in lung cancer. *Oncogene* **17**: 1557–1565.
- Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *Journal of Biological Chemistry* **283**: 1026–1033.
- Gao Y, Zhang W, Liu C, Li G (2019). miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. *Scientific Reports* **9**: 1–6.
- Garofalo M, Quintavalle C, Romano G, Croce MC, Condorelli G (2012). miR221/222 in cancer: Their role in tumor progression and response to therapy. *Current Molecular Medicine* **12**: 27–33.
- Gong C, Nie Y, Qu S, Liao JY, Cui X, Yao H, Zeng Y, Su F, Song E, Liu Q (2014). miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. *Cancer Research* **74**: 4341–4352.
- Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nature Cell Biology* **10**: 593–601.
- Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R (2004). The Microprocessor complex mediates the genesis of microRNAs. *Nature* **432**: 235–240.
- Guo D, Guo J, Li X, Guan F (2018). Enhanced motility and proliferation by miR-10b/FUT8/p-AKT axis in breast cancer cells. *Oncology Letters* **16**: 2097–2104.
- Halachmi N, Halachmi S, Evron E, Cairns P, Okami K et al. (1998). Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. *Genes, Chromosomes and Cancer* **23**: 239–243.
- Han M, Liu M, Wang Y, Chen X, Xu J et al. (2012a). Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. *PLoS One* **7**: e39520.
- Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C (2012b). Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. *Molecular and Cellular Biochemistry* **363**: 427–436.
- Han M, Wang F, Gu Y, Pei X, Guo G et al. (2016). MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF- β pathways. *Oncology Reports* **35**: 73–80.
- Hassan O, Ahmad A, Sethi S, Sarkar FH (2012). Recent updates on the role of microRNAs in prostate cancer. *Journal of Hematology & Oncology* **5**.
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D et al. (2005). A microRNA polycistron as a potential human oncogene. *Nature* **435**: 828–833.
- Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M (2016). The role of oncomirs in the pathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy* **78**: 129–139.
- Hesari Z, Nourbakhsh M, Hosseinkhani S, Abdolvahabi Z, Alipour M et al. (2018). Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells. *Gene* **673**: 149–158.
- Höck J, Meister G (2008). The Argonaute protein family. *Genome Biology* **9**: 1–8.
- Hong T, Ding J, Li W (2019). Mir-7 reverses breast cancer resistance to chemotherapy by targeting MRP1 and BCL2. *Oncotargets and Therapy* **12**: 11097.
- Hossain A, Kuo MT, Saunders GF (2006). Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. *Molecular and Cellular Biology* **26**: 8191–8201.
- Huang Q, Gumireddy K, Schrier M, Le Sage C, Nagel R et al. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nature Cell Biology* **10**: 202–210.
- Imani S, Zhang X, Hosseinfard H, Fu S, Fu J (2017). The diagnostic role of microRNA-34a in breast cancer: A systematic review and meta-analysis. *Oncotarget* **8**: 23177.
- Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A et al. (2009). microRNA-205 regulates HER3 in human breast cancer. *Cancer Research* **69**: 2195–2200.
- Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R et al. (2005). MicroRNA gene expression deregulation in human breast cancer. *Cancer Research* **65**: 7065–7070.
- Jerde TJ (2015). Phosphatase and tensin homologue: Novel regulation by developmental signaling. *Journal of Signal Transduction* **2015**: 282567.
- Jiang CF, Shi ZM, Li DM, Qian YC, Ren Y et al. (2018). Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. *Molecular Cancer* **17**: 1–8.
- Jiang M, Zhang W, Zhang R, Liu P, Ye Y et al. (2020). Cancer exosome-derived miR-9 and miR-181a promote the

- development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. *Oncogene* **39**: 4681–4694.
- Jiang Y, Jia Y, Zhang L (2017). Role of programmed cell death 4 in diseases: A double-edged sword. *Cellular & Molecular Immunology* **14**: 884–886.
- Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R et al. (2005). RAS is regulated by the let-7 microRNA family. *Cell* **120**: 635–647.
- Kashyap S, Pal S, Chandan G, Saini V, Chakrabarti S et al. (2021). Understanding the cross-talk between human microbiota and gastrointestinal cancer for developing potential diagnostic and prognostic biomarkers. *Seminars in Cancer Biology*, S1044–S579X(21)00121-8. DOI 10.1016/j.semcancer.2021.04.020. Epub ahead of print.
- Kawaguchi T, Yan L, Qi Q, Peng X, Gabriel EM et al. (2017). Overexpression of suppressive microRNAs, miR-30a and miR-200c are associated with improved survival of breast cancer patients. *Scientific Reports* **7**: 1–2.
- Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D et al. (2012). MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF- κ B and TGF- β signaling pathways. *Oncogene* **31**: 4150–4163.
- Khan S, Greco D, Michailidou K, Milne RL, Muranen TA et al. (2014). MicroRNA related polymorphisms and breast cancer risk. *PLoS One* **9**: e109973.
- Kia V, Paryan M, Mortazavi Y, Biglari A, Mohammadi-Yeganeh S (2019). Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells. *Journal of Cellular Biochemistry* **120**: 5666–5676.
- Kim EJ, Kim JS, Lee S, Lee H, Yoon JS et al. (2019). QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth. *International Journal of Cancer* **145**: 1585–1595.
- Kim J, Siverly AN, Chen D, Wang M, Yuan Y et al. (2016). Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways. *Cancer Research* **76**: 6424–6435.
- Kim J, Yao F, Xiao Z, Sun Y, Ma L (2018). MicroRNAs and metastasis: Small RNAs play big roles. *Cancer and Metastasis Reviews* **37**: 5–15.
- Kim S, Lee E, Jung J, Lee JW, Kim HJ et al. (2018). microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. *Oncogene* **37**: 2982–2991.
- Kim VN (2005). MicroRNA biogenesis: Coordinated cropping and dicing. *Nature Reviews Molecular Cell Biology* **6**: 376–385.
- Klinge CM (2018). Non-coding RNAs in breast cancer: Intracellular and intercellular communication. *Non-Coding RNA* **4**: 40.
- Kobayashi H, Tomari Y (2016). RISC assembly: Coordination between small RNAs and Argonaute proteins. *Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mechanisms* **1859**: 71–81.
- Kong W, Yang H, He L, Zhao JJ, Coppola D et al. (2008). MicroRNA-155 is regulated by the transforming growth factor β /Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. *Molecular and Cellular Biology* **28**: 6773–6784.
- Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012). microRNAs in cancer management. *Lancet Oncology* **13**: e249–e258.
- Kroczyńska B, Sharma B, Eklund EA, Fish EN, Platanius LC (2012). Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. *Molecular and Cellular Biology* **32**: 2809–2822.
- Ku BM, Ryu HW, Lee YK, Ryu J, Jeong JY et al. (2010). 4'-Acetoamido-4-hydroxychalcone, a chalcone derivative, inhibits glioma growth and invasion through regulation of the tropomyosin 1 gene. *Biochemical and Biophysical Research Communications* **402**: 525–530.
- Lee JA, Lee HY, Lee ES, Kim I, Bae JW (2011). Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. *Journal of Breast Cancer* **14**: 269–275.
- Lee Y, Kim M, Han J, Yeom KH, Lee S et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. *EMBO Journal* **23**: 4051–4060.
- Li B, Lu Y, Yu L, Han X, Wang H et al. (2017). miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF- κ B/COX-2 activation. *Chemico-Biological Interactions* **277**: 33–42.
- Li L, Yuan L, Luo J, Gao J, Guo J, Xie X (2013). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. *Clinical and Experimental Medicine* **13**: 109–117.
- Li M, Pan M, Wang J, You C, Zhao F et al. (2020). MiR-7 reduces breast cancer stem cell metastasis via inhibiting RELA to decrease ESAM expression. *Molecular Therapy-Oncolytics* **18**: 70–82.
- Li S, Yang X, Yang J, Zhen J, Zhang D (2016). Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. *Clinical and Experimental Medicine* **16**: 29–35.
- Li W, Ruan K (2009). MicroRNA detection by microarray. *Analytical and Bioanalytical Chemistry* **394**: 1117–1124.
- Li X, Zeng Z, Wang J, Wu Y, Chen W et al. (2020). MicroRNA-9 and breast cancer. *Biomedicine & Pharmacotherapy* **122**: 109687.
- Li Y, Wang Y, Fan H, Zhang Z, Li N (2018). miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522. *Biochemical and Biophysical Research Communications* **504**: 277–282.
- Li ZH, Weng X, Xiong QY, Tu JH, Xiao A et al. (2017). miR-34a expression in human breast cancer is associated with drug resistance. *Oncotarget* **8**: 106270.
- Liang YK, Lin HY, Dou XW, Chen M, Wei XL et al. (2018). MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. *NPJ Breast Cancer* **4**: 1–9.
- Liao XH, Xiang Y, Yu CX, Li JP, Li H et al. (2017). STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. *Oncotarget* **8**: 15763.
- Lin X, Chen W, Wei F, Zhou BP, Hung MC et al. (2017). Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly. *Theranostics* **7**: 4805.
- Liu DZ, Chang B, Li XD, Zhang QH, Zou YH (2017). MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. *Clinical and Translational Oncology* **19**: 1133–1140.
- Liu R, Li H, Liu L, Yu J, Ren X (2012). Fibroblast activation protein: A potential therapeutic target in cancer. *Cancer Biology & Therapy* **13**: 123–129.
- Liu S, Wang Z, Liu Z, Shi S, Zhang Z et al. (2018). miR-221/222 activate the Wnt/ β -catenin signaling to promote

- triple-negative breast cancer. *Journal of Molecular Cell Biology* **10**: 302–315.
- Lo PK, Wolfson B, Zhou X, Duru N, Gernapudi R et al. (2016). Non-coding RNAs in breast cancer. *Briefings in Functional Genomics* **15**: 200–221.
- Lu QL, Abel P, Foster CS, Lalani EN (1996). *bcl-2*: Role in epithelial differentiation and oncogenesis. *Human Pathology* **27**: 102–110.
- Luthra R, Singh RR, Luthra MG, Li YX, Hannah C et al. (2008). MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers. *Oncogene* **27**: 6667–6678.
- Lv C, Li F, Li X, Tian Y, Zhang Y et al. (2017). MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. *Nature Communications* **8**: 1–8.
- M'hamed IF, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ et al. (2017). miR-10b, miR-26a, miR-146a And miR-153 expression in triple negative vs. non triple negative breast cancer: Potential biomarkers. *Pathology & Oncology Research* **23**: 815–827.
- Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B et al. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. *Nature Biotechnology* **28**: 341–347.
- Ma L, Teruya-Feldstein J, Weinberg RA (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* **449**: 682–688.
- Ma L, Young J, Prabhala H, Pan E, Mestdagh P et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nature Cell Biology* **12**: 247–256.
- MacFarlane LA, R Murphy P (2010). MicroRNA: Biogenesis, function and role in cancer. *Current Genomics* **11**: 537–561.
- Manne U, Weiss HL, Grizzle WE (2000). Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. *International Journal of Cancer* **89**: 423–430.
- Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L et al. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Molecular Cancer* **5**: 24.
- Mayr C, Hemann MT, Bartel DP (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* **315**: 1576–1579.
- Meerson A, Eliraz Y, Yehuda H, Knight B, Crundwell M et al. (2019). Obesity impacts the regulation of miR-10b and its targets in primary breast tumors. *BMC Cancer* **19**: 1–0.
- Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST et al. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* **133**: 647–658.
- Meng T, Shang N, Nsabimana A, Ye H, Wang H, Wang C, Zhang Y (2020). An enzyme-free electrochemical biosensor based on target-catalytic hairpin assembly and Pd@UiO-66 for the ultrasensitive detection of microRNA-21. *Analytica Chimica Acta* **1138**: 59–68.
- Mi Y, Liu F, Liang X, Liu S, Huang X et al. (2019). Tumor suppressor let-7a inhibits breast cancer cell proliferation, migration and invasion by targeting MAGE-A1. *Neoplasia* **66**: 54–62.
- Moazzeni H, Najafi A, Khani M (2017). Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. *Molecular and Cellular Probes* **34**: 45–52.
- Mu F, Huang J, Xing T, Jing Y, Cui T et al. (2019). The Wnt/ β -catenin/Lef1 pathway promotes cell proliferation at least in part through direct upregulation of miR-17-92 cluster. *Frontiers in Genetics* **10**: 525.
- Negrini M, Calin GA (2008). Breast cancer metastasis: A microRNA story. *Breast Cancer Research* **10**: 1–4.
- O'Brien J, Hayder H, Zayed Y, Peng C (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology* **9**: 402.
- O'Day E, Lal A (2010). MicroRNAs and their target gene networks in breast cancer. *Breast Cancer Research* **12**: 1–0.
- Pan H, Gu L, Liu B, Li Y, Wang Y et al. (2017). Tropomyosin-1 acts as a potential tumor suppressor in human oral squamous cell carcinoma. *PLoS One* **12**: e0168900.
- Petri BJ, Klinge CM (2020). Regulation of breast cancer metastasis signaling by miRNAs. *Cancer and Metastasis Reviews* **39**: 837–886.
- Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS (2011). Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. *Cancer Research* **71**: 5579–5587.
- Qattan A, Intabli H, Alkhalayal W, Eltabache C, Tweigieri T, Amer SB (2017). Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. *BMC Cancer* **17**.
- Qi L, Bart J, Tan LP, Platteel I, van der Sluis T et al. (2009). Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma *in situ* and invasive carcinoma. *BMC Cancer* **9**: 1–8.
- Quan D, Chen K, Zhang J, Guan Y, Yang D, Wu H, Wu S, Lv L (2020). Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer. *Journal of Cellular Physiology* **235**: 3372–3381.
- Rahim A, Afzal M, Naveed AK (2019). Genetic polymorphism of miRNA-196a and its target gene annexin-A1 expression based on ethnicity in Pakistani female breast cancer patients. *Pakistan Journal of Medical Sciences* **35**: 1598.
- Rastogi YR, Saini AK, Thakur VK, Saini RV (2020). New insights into molecular links between microbiota and gastrointestinal cancers: A literature review. *International Journal of Molecular Sciences* **9**: 3212.
- Rao X, Di Leva G, Li M, Fang F, Devlin C et al. (2011). MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. *Oncogene* **30**: 1082–1097.
- Reddy SD, Ohshiro K, Rayala SK, Kumar R (2008). MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. *Cancer Research* **68**: 8195–8200.
- Ren YQ, Wang HJ, Zhang YQ, Liu YB (2017). WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206. *Cancer Chemotherapy and Pharmacology* **79**: 1003–1011.
- Rui X, Zhao H, Xiao X, Wang L, Mo L et al. (2018). MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1. *Experimental and Therapeutic Medicine* **16**: 4387–4392.
- Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H et al. (2000). Allelic imbalance and mutations of the PTEN gene in ovarian cancer. *International Journal of Cancer* **85**: 160–165.
- Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S et al. (2017). miR-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway. *Clinical Cancer Research* **23**: 1091–1103.
- Santolla MF, Lappano R, Cirillo F, Rigracciolo DC, Sebastiani A et al. (2018). miR-221 stimulates breast cancer cells and

- cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. *Journal of Experimental & Clinical Cancer Research* **37**: 1–2.
- Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, Modarressi MH (2012). Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. *Asian Pacific Journal of Cancer Prevention* **13**: 873–877.
- Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC (2007). Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. *Journal of Biological Chemistry* **282**: 1479–1486.
- Selcuklu SD, Donoghue MT, Spillane C (2009). miR-21 as a key regulator of oncogenic processes. *Biochemical Society Transactions* **37**: 918–925.
- Shao X, Tandon R, Samara G, Kanki H, Yano H et al. (1998). Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. *International Journal of Cancer* **77**: 684–688.
- Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'leary JJ et al. (2010). Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. *Nature Immunology* **11**: 141–147.
- Shen L, Wan Z, Ma Y, Wu L, Liu F et al. (2015). The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers. *Tumor Biology* **36**: 1993–2005.
- Shen M, Dong C, Ruan X, Yan W, Cao M et al. (2019). Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2. *Cancer Research* **79**: 3608–3621.
- Sheng P, Fields C, Aadland K, Wei T, Kolaczowski O et al. (2018). Dicer cleaves 5'-extended microRNA precursors originating from RNA polymerase II transcription start sites. *Nucleic Acids Research* **46**: 5737–5752.
- Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z (2010). MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. *Brain Research* **1352**: 255–264.
- Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS et al. (2012). Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. *Journal of Pathology* **227**: 357–366.
- Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P et al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. *Cell* **138**: 592–603.
- Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007). miR-21-mediated tumor growth. *Oncogene* **26**: 2799–2803.
- Singh P, Wedeken L, Waters LC, Carr MD, Klempnauer KH (2011). Pdc4 directly binds the coding region of c-myc mRNA and suppresses its translation. *Oncogene* **30**: 4864–4873.
- Singh R, Mo YY (2013). Role of microRNAs in breast cancer. *Cancer Biology & Therapy* **14**: 201–212.
- Song X, Liang Y, Sang Y, Li Y, Zhang H et al. (2020). CircHMCU promotes proliferation and metastasis of breast cancer by sponging the let-7 family. *Molecular Therapy-Nucleic Acids* **20**: 518–533.
- Sørli T, Tibshirani R, Parker J, Hastie T, Marron JS et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proceedings of The National Academy of Sciences of The United States of America* **100**: 8418–8423.
- Steiner E, Klubert D, Knutson D (2008). Assessing breast cancer risk in women. *American Family Physician* **78**: 1361–1366.
- Stoddard II FR, Brooks AD, Eskin BA, Johannes GJ (2008). Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. *International Journal of Medical Sciences* **5**: 189.
- Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. *Federation of European Biochemical Societies Letters* **582**: 1564–1568.
- Sun X, Wang H, Jian Y, Lan F, Zhang L et al. (2018). Ultrasensitive microfluidic paper-based electrochemical/visual biosensor based on spherical-like cerium dioxide catalyst for miR-21 detection. *Biosensors and Bioelectronics* **105**: 218–225.
- Tang CP, Zhou HJ, Qin J, Luo Y, Zhang T (2017). MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer. *Oncology Reports* **38**: 3144–3152.
- Tang J, Ahmad A, Sarkar FH (2012). The role of microRNAs in breast cancer migration, invasion and metastasis. *International Journal of Molecular Sciences* **13**: 13414–13437.
- Tang X, Tu G, Yang G, Wang X, Kang L et al. (2019). Autocrine TGF- β 1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation. *Cancer Letters* **452**: 79–89.
- Taplin S, Abraham L, Barlow WE, Fenton JJ, Berns EA et al. (2008). Mammography facility characteristics associated with interpretive accuracy of screening mammography. *Journal of the National Cancer Institute* **100**: 876–887.
- Tvingsholm SA, Hansen MB, Clemmensen KK, Brix DM, Rafn B et al. (2018). Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1. *Oncogenesis* **7**: 1–5.
- Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y et al. (2010). miR-200bc/429 cluster targets PLC γ 1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. *Oncogene* **29**: 4297–4306.
- Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM et al. (2009). RETRACTED: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell* **137**: 1032–1046.
- van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY et al. (2015). Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. *Breast Cancer Research* **17**: 1–5.
- Várallyay E, Burgyán J, Havelda Z (2008). MicroRNA detection by northern blotting using locked nucleic acid probes. *Nature Protocols* **3**: 190.
- Wahid F, Shehzad A, Khan T, Kim YY (2010). MicroRNAs: synthesis, mechanism, function, and recent clinical trials. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* **1803**: 1231–1243.
- Wang H, He D, Wan K, Sheng X, Cheng H et al. (2020). In situ multiplex detection of serum exosomal microRNAs using an all-in-one biosensor for breast cancer diagnosis. *Analyst* **145**: 3289–3296.
- Wang H, Tan Z, Hu H, Liu H, Wu T et al. (2019). microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. *BMC Cancer* **19**: 1–3.
- Wang J, Guan J, Lu Z, Jin J, Cai Y, Wang C, Wang F (2015). Clinical and tumor significance of tropomyosin-1 expression levels in renal cell carcinoma. *Oncology Reports* **33**: 1326–1334.
- Wang J, Tang C, Yang C, Zheng Q, Hou Y (2019). Tropomyosin-1 functions as a tumor suppressor with respect to cell proliferation, angiogenesis and metastasis in renal cell carcinoma. *Journal of Cancer* **10**: 2220.

- Wang L, Guo J, Wang Q, Zhou J, Xu C et al. (2014). LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β -catenin. *Journal of Cancer Research and Clinical Oncology* **140**: 1997–2008.
- Wang L, Kang FB, Wang J, Yang C, He DW (2019). Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway. *Anti-Cancer Drugs* **30**: 225.
- Wang JL, Sun SJ, Zhang J, Wang GN (2017). Prognostic value of circulating microRNA-21 for breast cancer: A systematic review and meta-analysis. *Artificial Cells, Nanomedicine, and Biotechnology* **45**: 1216–1221.
- Wang X, Qiu H, Tang R, Song H, Pan H et al. (2018). miR-30a inhibits epithelial-mesenchymal transition and metastasis in triple-negative breast cancer by targeting ROR1. *Oncology Reports* **39**: 2635–2643.
- Wang Y, Zhang X, Chao Z, Kung HF, Lin MC et al. (2017). MiR-34a modulates ErbB2 in breast cancer. *Cell Biology International* **41**: 93–101.
- Wei N, Liu SS, Chan KK, Ngan HY (2012). Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. *PLoS One* **7**: e30311.
- Wei Q, Chen Y, Gu YF, Zhao W (2019). Molecular characterization and functional analysis of leucine zipper transcription factor like 1 in zebrafish (*Danio rerio*). *Frontiers in Physiology* **10**: 801.
- Wei Q, Chen ZH, Wang L, Zhang T, Duan L et al. (2016). LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells. *Oncogene* **35**: 2655–2663.
- Wei Q, Zhou W, Wang W, Gao B, Wang L, Cao J, Liu ZP (2010). Tumor-suppressive functions of leucine zipper transcription factor-like 1. *Cancer Research* **70**: 2942–2950.
- Welch C, Chen Y, Stallings RL (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. *Oncogene* **26**: 5017–5022.
- Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y et al. (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. *Nucleic Acids Research* **37**: 2584–2595.
- Wilczynska A, Bushell Martin (2015). The complexity of miRNA-mediated repression. *Cell Death & Differentiation* **22**: 22–33.
- Wu L, Fan J, Belasco JG (2006). MicroRNAs direct rapid deadenylation of mRNA. *Proceedings of the National Academy of Sciences of the United States of America* **103**: 4034–4039.
- Xiang Y, Liao XH, Yao A, Qin H, Fan LJ et al. (2017). MRTF-A-miR-206-WDR1 form feedback loop to regulate breast cancer cell migration. *Experimental Cell Research* **359**: 394–404.
- Xiao B, Shi X, Bai J (2019). miR-30a regulates the proliferation and invasion of breast cancer cells by targeting Snail. *Oncology Letters* **17**: 406–413.
- Yager JD, Davidson NE (2006). Estrogen carcinogenesis in breast cancer. *New England Journal of Medicine* **354**: 270–282.
- Yan GR, Xu SH, Tan ZL, Liu L, He QY (2011). Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. *Proteomics* **11**: 912–920.
- Yan L, Yu MC, Gao GL, Liang HW, Zhou XY et al. (2018). MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. *Journal of Cellular Biochemistry* **119**: 8773–8783.
- Yan LX, Huang XF, Shao Q, Huang MY, Deng L et al. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA* **14**: 2348–2360.
- Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH (2004). A novel function of the MA-3 domains in transformation and translation suppressor Pdc4 is essential for its binding to eukaryotic translation initiation factor 4A. *Molecular and Cellular Biology* **24**: 3894–3906.
- Yang LW, Wu XJ, Liang Y, Ye GQ, Che Y et al. (2020). miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5. *Molecular Carcinogenesis* **59**: 447–461.
- Yang W, Wang X, Zheng W, Li K, Liu H, Sun Y (2013). Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. *International Journal of Oncology* **42**: 690–698.
- Ye J, Xu M, Tian X, Cai S, Zeng S (2019). Research advances in the detection of miRNA. *Journal of Pharmaceutical Analysis* **9**: 217–226.
- Yu F, Yao H, Zhu P, Zhang X, Pan Q et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* **131**: 1109–1123.
- Yu RM, Cheah YK (2017). The roles of miRNAs in human breast cancer and canine mammary tumor. *Applied Cancer Research* **37**: 37.
- Yu Z, Wang C, Wang M, Li Z, Casimiro MC et al. (2008). A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. *Journal of Cell Biology* **182**: 509–517.
- Zhang HD, Jiang LH, Sun DW, Li J, Tang JH (2017). miR-30a inhibits the biological function of breast cancer cells by targeting Notch1. *International Journal of Molecular Medicine* **40**: 1235–1242.
- Zhang M (2002). *The role of maspin in tumor progression and normal development*, pp. 96–114. Maspin. Landes Bioscience.
- Zhang W, Chen CJ, Guo GL (2018). MiR-155 promotes the proliferation and migration of breast cancer cells via targeting SOCS1 and MMP16. *European Review for Medical and Pharmacological Sciences* **22**: 7323–7332.
- Zhao J, Tao Y, Zhou Y, Qin N, Chen C et al. (2015). MicroRNA-7: A promising new target in cancer therapy. *Cancer Cell International* **15**: 1–8.
- Zhao ZL, Cai Y, Wang YY, Xia CL, Li CX et al. (2015). Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells. *Zhejiang Da Xue Xue Bao. Yi Xue Ban* **44**: 400–409.
- Zhou XL, Wang M (2015). Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. *Genetics and Molecular Research* **14**: 17059–17067.
- Zhou Y, Wang M, Tong Y, Liu X, Zhang L et al. (2019). miR-206 promotes cancer progression by targeting full-length neurokinin-1 receptor in breast cancer. *Technology in Cancer Research & Treatment* **18**: 1533033819875168.
- Zhu S, Si ML, Wu H, Mo YY (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). *Journal of Biological Chemistry* **282**: 14328–14336.
- Zhu S, Wu H, Wu F, Nie D, Sheng S et al. (2008). MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. *Cell Research* **18**: 350–359.
- Zong Y, Zhang Y, Sun X, Xu T, Cheng X, Qin Y (2019). miR-221/222 promote tumor growth and suppress apoptosis by targeting lncRNA GAS5 in breast cancer. *Bioscience Reports* **39**: BSR20181859.